|
Regeneron Pharmaceuticals |
|
|
777 Old Saw Mill River Road
Tarrytown, NY 10591 USA
phone:(914) 345-7400
fax:(914) 347-2847
|
|
| Symbol |
REGN |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
644 |
|
|
| www.regeneron.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| New product candidates in cancer, eye diseases, and inflammation. |
|
| Management |
| Leonard S. Schleifer, MD, PhD, President and Chief Executive Officer; George D. Yancopoulos, MD, PhD, Executive Vice President, Chief Scientific Officer and President; Murray A. Goldberg, Senior Vice President, Finance and Administration, Chief Financial Office; Stuart A. Kolinski, Senior Vice President, General Counsel and Secretary; Peter Powchik, MD, Senior Vice President, Clinical Development |
| |
|
|
|
|
|
|
|
| Keywords |
| rilonacept, cancer, eye diseases, inflammatory diseases, sanofi-aventis |
|
|
|
| Description |
|
Regeneron has a growing portfolio of product candidates, entering all stages of clinical testing required for product approval. The company focuses on unmet clinical needs, and is developing new product candidates in diverse fields such as cancer, eye diseases, and inflammation. |
|
| Technology / Differentiation |
| VelociGene and VelociMouse are designed to aid in the identification of specific genes of therapeutic interest for a particular disease or cell type and validate targets through high-throughput production of mammalian models. VelocImmune is used to generate fully-human monoclonal antibodies to address clinically relevant targets of therapeutic interest. Traps are designed to trap specific extracellular signaling molecules (such as cytokines and growth factors) and may be used to block the activity of these molecules in certain disease settings. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
